{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red255\green255\blue174;
\red183\green242\blue206;
\red37\green37\blue37;
\red33\green33\blue33;
\red255\green210\blue183;
\red119\green119\blue119;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red14\green86\blue140;
\red255\green255\blue102;
\red80\green80\blue80;
\red51\green51\blue51;
\red56\green124\blue43;
\red204\green204\blue204;
\red151\green151\blue151;
\red0\green114\blue54;
\red112\green112\blue112;
\red106\green144\blue39;
\red21\green137\blue21;
\red255\green248\blue96;
\red247\green247\blue247;
\red239\green122\blue2;
\red107\green107\blue106;
\red232\green233\blue232;
\red249\green249\blue249;
\red249\green250\blue251;
\red228\green231\blue232;
\red254\green254\blue0;
\red181\green79\blue104;
\red233\green233\blue233;
\red203\green203\blue203;
\red127\green127\blue127;
\red245\green245\blue245;
\red71\green120\blue194;
\red190\green190\blue252;
\red255\green194\blue211;
\red187\green187\blue187;
\red242\green242\blue242;
\red240\green240\blue240;
\red105\green105\blue105;
\red204\green255\blue255;
\red236\green236\blue236;
\red61\green61\blue61;
\red188\green41\blue30;
\red190\green237\blue228;
\red229\green243\blue255;
\red179\green218\blue255;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red208\green208\blue208;
\red227\green227\blue227;
\red255\green191\blue101;
\red149\green246\blue220;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red118\green118\blue118;
\red172\green172\blue172;
\red9\green56\blue84;
\red212\green212\blue212;
\red102\green102\blue102;
\red240\green248\blue255;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 Source Sans Pro;}{
\f6 serif;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid-1144584166\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid863404360}
}
{\*\listoverridetable
{\*\listoverride{\listid863404360\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Cleveland Clinic Foundation v. True Health Diagnostics LLC, 760 Fed.Appx. 1013 (2019)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_71}{\*\bkmkend co_document_71}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I97f4851055ca11e98ad7980ccbaa346a_Target}{\*\bkmkend I97f4851055ca11e98ad7980ccbaa346a_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_71}{\*\bkmkend co_readingModeKC_71}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_71}{\*\bkmkend co_readingModeCitatorFlag_71}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I97f4851055ca11e98ad7980ccbaa346a&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_71}{\*\bkmkend co_readingModeNegativeTreatment_71}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Distinguished by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/I8efea0b0d5aa11ea8f20d69dbf9d7d73/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI8efea0b0d5aa11ea8f20d69dbf9d7d73%26ss%3D2047911688%26ds%3D2051571689%26origDocGuid%3DI97f4851055ca11e98ad7980ccbaa346a&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=25ba8d0a9e13498ba250f84a7948bf66&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Illumina, Inc. v. Ariosa Diagnostics, Inc.
}
{\b0 \cf28 \f2 \i0 \fs16 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Fed.Cir.(Cal.), 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
March 17, 2020
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
760 Fed.Appx. 1013
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This case was not selected for publication in West\rquote s Federal Reporter.
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
See Fed. Rule of Appellate Procedure 32.1 generally governing citation of judicial decisions issued on or after Jan. 1, 2007. See also U.S.Ct. of App. Fed. Cir. Rule 32.1.
\par 
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States Court of Appeals, Federal Circuit.
\par 
}
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
CLEVELAND CLINIC FOUNDATION, Cleveland HeartLab, Inc., Plaintiffs-Appellants
\par 
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf21 \f4 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5046704989)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf28 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
TRUE HEALTH DIAGNOSTICS LLC
}}}
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, Defendant-Appellee
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2018-1218
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Decided: April 1, 2019
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_71}{\*\bkmkend co_synopsis_71}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Owner of patents disclosing diagnostic tests which could be used to determine whether an individual was at a lower risk or higher risk of developing or having cardiovascular disease brought infringement action. Competitor moved to dismiss based on patent invalidity. The United States District Court for the Eastern District of Virginia, No. 1:17-cv-00198-LMB-IDD, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0147684601&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Leonie M. Brinkema
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042320242&pubNum=0000999&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2017 WL 3381976
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, granted motion. Patent owner appealed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court of Appeals, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0225327201&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lourie
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Circuit Judge, held that claims were directed to a natural law, as would support finding of patent ineligibility.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Affirmed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_1014_71}{\*\bkmkend co_pp_sp_6538_1014_71}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1014
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Appeal from the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1991206308&pubNum=0003024&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court for the Eastern District of Virginia in No. 1
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
:17-cv-00198-LMB-IDD, Judge Leonie M. Brinkema.
\par 
}
}
}
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_71}{\*\bkmkend co_attorneysAndLawFirms_71}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0219436401&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lawrence D. Rosenberg
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0177049701&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jones Day
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Washington, DC, argued for plaintiffs-appellants. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0318310601&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Susan M. Gerber
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0114174301&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Calvin Griffith
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Cleveland, OH.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0337247201&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Adam Louis Marchuk
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Perkins Coie LLP, Chicago, IL, argued for defendant-appellee. Also represented by Mark T. Smith; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0175349501&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dan L. Bagatell
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Hanover, NH.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0318050201&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David Movius
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, McDonald Hopkins LLC, Cleveland, OH, for amicus curiae Raymond A. Mercado.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0334411101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Scott A. M. Chambers
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Porzio, Bromberg & Newman, PC, Washington, DC, for amici curiae Walter Matystik, Adam Mossoff, Kristen J. Osenga, Michael Risch, Ted M. Sichelman, David O. Taylor. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0513672701&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Matthew Zapadka
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Bass, Berry & Sims, PLC, Washington, DC.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0225327201&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lourie
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0368246101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moore
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0126887301&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Wallach
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Circuit Judges.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_71}{\*\bkmkend co_opinion_71}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Opinion
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I3d9bc433090f11eb9c0dba44a5861}{\*\bkmkend co_anchor_I3d9bc433090f11eb9c0dba44a5861}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0225327201&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lourie
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, Circuit Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I3db58dc1090f11eb9c0dba44a5861}{\*\bkmkend co_anchor_I3db58dc1090f11eb9c0dba44a5861}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Cleveland Clinic Foundation and Cleveland HeartLab, Inc., (collectively, \u8220\'3fCleveland Clinic\u8221\'3f) appeal from a decision of the United States District Court for the Eastern District of Virginia, dismissing their complaint for patent infringement under Rule 12(b)(6) and holding claim 1 of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent 9,575,065 (the \u8220\'3f\u8217\'3f065 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claims 1 and 2 of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041153527&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=I9c6cbe90024911e785909b2663de9600&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent 9,581,597 (the \u8220\'3f\u8217\'3f597 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as directed to an ineligible natural law. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_1015_71}{\*\bkmkend co_pp_sp_6538_1015_71}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1015
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042320242&pubNum=0000999&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Foundation v. True Health Diagnostics, LLC
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 1:17-cv-00198-LMB-IDD, 2017 WL 3381976 (E.D. Va. Aug. 4, 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042320242&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Decision 
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f). Because the district court correctly concluded that the claims are directed to a natural law and recite no other inventive concept, we 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
affirm
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I3db69f31090f11eb9c0dba44a5861}{\*\bkmkend co_anchor_I3db69f31090f11eb9c0dba44a5861}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Background
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patents at issue
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012047911688_ID0EVEAE_71}{\*\bkmkend co_fnRef_B00012047911688_ID0EVEAE_71}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012047911688_71" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 disclose \u8220\'3fdiagnostic test[s] which can be used to determine whether an individual ... is at a lower risk or higher risk of developing or having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f065 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 ll. 21\u8211\'3f25. These diagnostic tests are \u8220\'3fbased on the discovery that patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=I05df828eff5111dc84008c7818c06073&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
coronary artery disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (CAD) have significantly greater levels of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iadf4fbaa475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
leukocyte
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and blood myeloperoxidase (MPO) levels.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. col. 2 ll. 36\u8211\'3f39.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
At the time of the invention, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fCVD\u8221\'3f) was understood to be multifactorial, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f065 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 l. 51\u8211\'3fcol. 2 l. 26, and scientists and physicians were developing predictive algorithms based on genetic, environmental, and lifestyle factors. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 l. 53\u8211\'3f60. How-ever, these factors alone did not fully predict an individual\rquote s risk of developing CVD; in particular, \u8220\'3fa large number of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disorders
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 occur[red] in individuals with apparently low to moderate risk profiles.\u8221\'3f Appellant Br. 6 (citation omitted). Thus, the patents disclose a need in the art for \u8220\'3f[d]iagnostic tests which employ risk factors that are independent of traditional CVD risk factors such as LDL levels.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f065 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 2 ll. 24\u8211\'3f26.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Myeloperoxidase (\u8220\'3fMPO\u8221\'3f) is a naturally-occurring heme protein associated with some types of white blood cells. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f065 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 6 ll. 60\u8211\'3f65. It functions as an oxidant, converting inert substrates to reactive oxygen species toxic to pathogens, to aid in phagocytosis, an important process in the body\rquote s immune system. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 7 ll. 4\u8211\'3f22. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica4a1895475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Atherosclerosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (the major cause of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=I05df828eff5111dc84008c7818c06073&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
coronary artery disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) was known to be \u8220\'3fa chronic inflammatory disorder,\u8221\'3f and high blood levels of other metabolites had been correlated to CVD. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 2 ll. 12\u8211\'3f21 (disclosing the then-recent discovery that plasma concentrations of C-reactive protein could predict an individual\rquote s risk of developing some types of CVD). But these metabolites are imperfect markers of CVD because they are not specific to cardiovascular inflammation. While MPO had been found to be present at elevated levels in atherosclerotic lesions, it had not been shown that MPO was present at elevated levels in blood samples from patients with atherosclerotic CVD. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 6 l. 66\u8211\'3fcol. 7 l. 3.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patents disclose several methods of measuring a patient\rquote s blood MPO level. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f065 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 8 ll. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8211\'3f36 (\u8220\'3fMyeloperoxidase activity may be determined by any of a variety of standard methods known in the art.\u8221\'3f). As is relevant to the claims, the patents disclose use of an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
enzyme-linked immunosorbent assay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fELISA\u8221\'3f), a well-known technique that quantifies the level of an antigen in a bodily sample by detecting its binding to a biochemically compatible antibody. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9 ll. 33\u8211\'3f
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe mass of myeloperoxidase in a given sample is readily determined by an immunological method, e.g.[,] ELISA. Commercial kits for MPO quantification by ELISA are available.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Example 1 discloses the results of a study of 326 patients and concludes that blood MPO levels strongly correlate with risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=I05df828eff5111dc84008c7818c06073&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
coronary artery disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 but not with traditional risk factors for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=I05df828eff5111dc84008c7818c06073&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
coronary artery disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f065 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 27 ll. 9\u8211\'3f59. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_1016_71}{\*\bkmkend co_pp_sp_6538_1016_71}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1016
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In the study, MPO mass was quantified with ELISA, specifically by using a commercially-available antibody modified to bind to MPO. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 24 ll. 11-13. Examples 3\u8211\'3f6 disclose experimental results, using other methods, showing that common oxidation products of MPO were present in significantly higher levels in blood samples from patients with coronary artery disease as compared to a control group. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 28 l. 45\u8211\'3fcol. 30 l. 30.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We previously addressed the subject matter eligibility of a parent patent, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent 7,223,552
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Foundation v. True Health Diagnostics LLC
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d 1352 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
cert. denied
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043637898&pubNum=0000708&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 138 S.Ct. 2621, 201 L.Ed.2d 1026 (2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic I 
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f). Claim 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was exemplary:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
11. A method of assessing a test subject\rquote s risk of having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, comprising
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
comparing levels of myeloperoxidase in a bodily sample from the test subject with levels of myeloperoxidase in comparable bodily samples from control subjects diagnosed as not having the disease, said bodily sample being blood, serum, plasma, blood 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iadf4fbaa475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
leukocytes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 selected from the group consisting of neutrophils, monocytes, sub-populations of neutrophils, and sub-populations of monocytes, or any combination thereo[f];
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein the levels of myeloperoxidase in the bodily [samples] from the test subject relative to the levels of [m]yeloperoxidase in the comparable bodily samples from control subjects is indicative of the extent of the test subject\rquote s risk of having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 30 ll. 47\u8211\'3f62.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic I
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we held these methods invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as directed to the ineligible natural law that blood MPO levels correlate with atherosclerotic CVD. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1360&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1360" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1360\u8211\'3f61
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that the claimed method \u8220\'3fstarts and ends\u8221\'3f with observation of \u8220\'3fnaturally occurring phenomena,\u8221\'3f as in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1371 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). We further held that, because the patent did not purport to have invented any of the biological techniques used to detect MPO or the statistical methods used to compare a patient\rquote s MPO levels to the control group, the claims recited no further inventive concept sufficient to transform the nature of the claims into a patent-eligible application of the natural law. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1361&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1361" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1361\u8211\'3f62
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 78, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Meanwhile, Cleveland Clinic was issued the patents in suit from continuation applications ultimately claiming priority from the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041153527&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=I9c6cbe90024911e785909b2663de9600&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f597 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is illustrative:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. A method for identifying an elevated myeloperoxidase (MPO) concentration in a plasma sample from a human subject with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
a) contacting a sample with an anti-MPO antibody, wherein said sample is a plasma sample from a human subject having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
b) spectrophotometrically detecting MPO levels in said plasma sample;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
c) comparing said MPO levels in said plasma sample to a standard curve generated with known amounts of MPO to determine the MPO concentration in said sample; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
d) comparing said MPO concentration in said plasma sample from said human subject to a control MPO concentration from apparently healthy human subjects, and identifying said 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_1017_71}{\*\bkmkend co_pp_sp_6538_1017_71}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1017
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 MPO concentration in said plasma sample from said human subject as being elevated compared to said control MPO concentration.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 2 further requires collecting the plasma sample by \u8220\'3fcentrifuging an anti-coagulated blood sample from said human subject.\u8221\'3f Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f065 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is directed to:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method of detecting elevated MPO mass in a patient sample comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
a) obtaining a plasma sample from a human patient having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (CVD); and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
b) detecting elevated MPO mass in said plasma sample, as compared to a control MPO mass level from the general population or apparently healthy subjects, by contacting said plasma sample with anti-MPO antibodies and detecting binding between MPO in said plasma sample and said anti-MPO antibodies.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
These claims recite methods of identifying and detecting MPO, in contrast to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3fs claimed method of assessing atherosclerotic CVD risk from blood MPO levels.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In February 2017, Cleveland Clinic filed a complaint against True Health Diagnostics LLC (\u8220\'3fTrue Health\u8221\'3f) for patent infringement in the Eastern District of Virginia. True Health moved to dismiss the counts of infringement of the asserted patents under Rule 12(b)(6). After our decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic I
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issued, the district court held the asserted claims ineligible as directed to a natural law under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and dismissed Cleveland Clinic\rquote s complaint for failure to state a claim. Cleveland Clinic appealed. We have jurisdiction under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1295&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_7b9b000044381" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1295(a)(1)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I3dc67db1090f11eb9c0dba44a5861}{\*\bkmkend co_anchor_I3dc67db1090f11eb9c0dba44a5861}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Discussion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We review a district court\rquote s order of dismissal under Rule 12 according to the law of the regional circuit. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039262742&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1347&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1347" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
BASCOM Glob. Internet Servs., Inc. v. AT & T Mobility LLC
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1341, 1347 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027859004&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1331&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1331" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re Bill of Lading Transmission & Processing Sys. Patent Litig.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 681 F.3d 1323, 1331 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). In the Fourth Circuit, Rule 12 dismissal is reviewed 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
de novo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and is appropriate when, assuming all well-pleaded facts are true and drawing all reasonable inferences in favor of the plaintiff, the complaint fails to allege \u8220\'3fsufficient facts to state a claim that is \u8216\'3fplausible on its face.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2024765453&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_440&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_440" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
E.I. du Pont de Nemours & Co. v. Kolon Indus., Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 637 F.3d 435, 440 (4th Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012293296&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_570&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_570" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bell Atl. Corp. v. Twombly
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. 544, 570, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides that \u8220\'3f[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But the Supreme Court has long interpreted these categories as excluding \u8220\'3flaws of nature, natural phenomena, and abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_185&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_185" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 185, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1852194692&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_175&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_175" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Le Roy v. Tatham
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 55 U.S.(14 How.) 156, 175, 14 L.Ed. 367 (1852)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[A] principle is not patentable. A principle, in the abstract, is a fundamental truth; an original cause; a motive; these cannot be patented, as no one can claim in either of them an exclusive right.\u8221\'3f). A claim to otherwise statutory subject matter does not become ineligible simply because it recites a natural law. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_590&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_590" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Parker v. Flook
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 437 U.S. 584, 590, 98 S.Ct. 2522, 57 L.Ed.2d 451 (1978)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But the Supreme Court has held that a claim directed to a natural law may nevertheless be patent-eligible if it \u8220\'3fcontain[s] other elements or a combination of elements, sometimes referred to as an \u8216\'3finventive concept,\u8217\'3f sufficient to ensure that the patent in practice amounts to significantly more 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_1018_71}{\*\bkmkend co_pp_sp_6538_1018_71}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1018
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 than a patent upon the natural law itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72\u8211\'3f73, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_594&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_594" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Flook
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 437 U.S. at 594, 98 S.Ct. 2522
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a question of law that can include subsidiary questions of fact. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043808569&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1128&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1128" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Aatrix Software, Inc. v. Green Shades Software, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 882 F.3d 1121, 1128 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Such factual issues may be resolved on the pleadings \u8220\'3fbased on the sources properly considered on a motion to dismiss, such as the complaint, the patent, and materials subject to judicial notice.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043808569&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2045678898&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1008&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1008" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Data Engine Techs. LLC v. Google LLC
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 906 F.3d 999, 1008 n.2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that relevant prosecution histories are \u8220\'3fpublic records\u8221\'3f properly considered at the pleadings stage) (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2000455818&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_957&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_957" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Hockerson-Halberstadt, Inc. v. Avia Grp. Int\rquote l, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 222 F.3d 951, 957 (Fed. Cir. 2000)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004103924&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Microsoft Corp. v. Multi-Tech Sys., Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 357 F.3d 1340, 1349 (Fed. Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[A patentee\rquote s] statement made during prosecution of [a continuation] patent is relevant to an understanding of the common disclosure in the sibling ... patents.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12047911688_71}{\*\bkmkend co_anchor_B12047911688_71}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cleveland Clinic argues that the claims are not directed to a natural law, but to the technique of using an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib5ba9392475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoassay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to measure the blood MPO levels of patients with atherosclerotic CVD. Cleveland Clinic further asserts that, in any case, the correlation between blood MPO levels and atherosclerotic CVD is not a natural law because it can only be detected using certain techniques. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
According to Cleveland Clinic, prior art techniques were either too invasive (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, detecting MPO in samples of excised atherosclerotic lesions) or failed to predict CVD risk (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a flow cytometry-based method called MPXI and an older technique for measuring MPO in white blood cells by staining). Cleveland Clinic also argues that, while performing an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib5ba9392475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoassay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on blood samples was known, using the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib5ba9392475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoassay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to detect the correlation between blood MPO levels and atherosclerotic CVD supplies an inventive concept sufficient to transform the claims into patent-eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
True Health responds that the correlation between atherosclerotic CVD and blood MPO levels is a natural law because it exists in nature apart from human intervention, regardless of the technique used to observe it. True Health further argues that using known techniques in a standard way to observe the natural law neither renders the claims directed to something other than this natural law nor supplies an additional inventive concept.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We agree with True Health and conclude, as we did in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic I
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, that the claims are directed to the natural law that blood MPO levels correlate with atherosclerotic CVD. Cleveland Clinic\rquote s primary argument to the contrary is that, unlike the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims, the claims at issue are not directed to \u8220\'3fassessing a test subject\rquote s risk of having atherosclerotic [CVD]\u8221\'3f by comparing the subject\rquote s MPO levels to a control group, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 30 ll. 47\u8211\'3f62, but rather to \u8220\'3ftechniques for detecting elevated levels of MPO in the blood of patients having CVD.\u8221\'3f Appellant Br. 3.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We find, however, as the district court did, that this distinction is \u8220\'3foverly superficial.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042320242&pubNum=0000999&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Decision
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2017 WL 3381976, at *8
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claims are not directed to new techniques for performing an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib5ba9392475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoassay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to detect a patient\rquote s blood MPO levels. They only recite applying known methods to detect MPO levels in plasma, comparing them to standard MPO levels, and reaching a conclusion: that the patient\rquote s blood MPO levels are 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
elevated
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in comparison to a control group. This conclusion is simply another articulation of the natural law that blood MPO levels correlate with atherosclerotic CVD. Thus, as we held in 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_1019_71}{\*\bkmkend co_pp_sp_6538_1019_71}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1019
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland
}
}
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 Clinic I
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the claims are directed to the patent-ineligible natural law that blood MPO levels correlate with risk of atherosclerotic CVD. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_593&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_593" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Flook
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 437 U.S. at 593, 98 S.Ct. 2522
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (stating that patent eligibility does not turn \u8220\'3fon the draftsman\rquote s art\u8221\'3f). The rephrasing of the claims does not make them less directed to a natural law.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nor is the fact that blood MPO levels correlate with atherosclerotic CVD any less a natural law because it can only be observed by use of certain techniques. Many scientific techniques will not reveal a correlation between blood MPO levels and atherosclerotic CVD. But the same is true of the natural laws at issue in our previous cases. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1376
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (that paternally inherited cffDNA is present in maternal blood plasma); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_747&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_747" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 915 F.3d 743, 747 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (that some 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myasthenia gravis
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patients \u8220\'3fgenerate autoantibodies to a membrane protein called MuSK\u8221\'3f). These laws of nature exist regardless of the methods used by humans to observe them. Inadequate measures of detection do not render a natural law any less natural. Thus, we held the claims at issue in those cases directed to a natural law, and we do so again here.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf28 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22047911688_71}{\*\bkmkend co_anchor_B22047911688_71}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Furthermore, the claims contain no additional inventive concept. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cleveland Clinic\rquote s argument to the contrary\u8212\'3fthat using a known technique in a standard way to observe a natural law can confer an inventive concept\u8212\'3fhas been consistently rejected by this court in circumstances nearly identical to this case. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_753&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_753" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 915 F.3d at 753\u8211\'3f54
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that there is no inventive concept in \u8220\'3fapplying standard techniques in a standard way to observe a natural law\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fFor process claims that encompass natural phenomenon, the process steps are the additional features that must be new and useful.\u8221\'3f (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_591&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_591" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Flook
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 437 U.S. at 591, 98 S.Ct. 2522
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Neither the specification nor the record discloses any technical impediment to using an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib5ba9392475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoassay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a standard way to measure MPO levels in blood. The patents disclose that an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib5ba9392475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoassay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was a known technique for measuring protein mass and never suggest that any significant adjustments needed to be made to accommodate its use for measuring blood MPO levels. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f065 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9 ll. 33\u8211\'3f
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Furthermore, the specification and prosecution history plainly concede that each of the process steps was well-known in the art. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 21 ll. 1\u8211\'3f30 (comparing patient\rquote s blood MPO levels to control sample was known); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 8 ll. 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8211\'3f36, col. 9 ll. 33\u8211\'3f
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 11 ll. 17\u8211\'3f19 (detecting blood MPO levels using an ELISA was known); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 24 ll. 16\u8211\'3f20 (determining MPO concentration from sample data using a standard curve was known). Furthermore, Cleveland Clinic quoted in its complaint statements from the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041153527&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=I9c6cbe90024911e785909b2663de9600&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f597 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 application\rquote s Notice of Allowability, that collecting a plasma sample, contacting the sample with an anti-MPO antibody, and spectrophotometrically detecting MPO binding to an anti-MPO antibody were known. J.A. 1140.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cleveland Clinic also argues that remand is warranted because the district court improperly resolved factual disputes against it at the pleadings stage. In view of our conclusion that the specification and prosecution history are clear that the claimed method uses a known technique in a standard way to observe a natural law, we decline to do so. There is no reason to task the district court with finding an inventive concept that the specification and prosecution history concede does not exist. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042886607&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_913&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_913" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Secured Mail Sols. LLC v. Universal Wilde, Inc.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 873 F.3d 905, 913 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that a court \u8220\'3fneed not \u8216\'3faccept 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_1020_71}{\*\bkmkend co_pp_sp_6538_1020_71}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1020
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as true allegations that contradict matters properly subject to judicial notice\u8217\'3f \u8221\'3f (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033807528&pubNum=0006538&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_6538_931&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_931" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Anderson v. Kimberly-Clark Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 570 F. App\rquote x 927, 931 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ) ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Finally, Cleveland Clinic argues that the district court failed to give the appropriate deference to 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
s
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
ubject matter eligibility guidance published by the PTO
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022047911688_ID0EHXAG_71}{\*\bkmkend co_fnRef_B00022047911688_ID0EHXAG_71}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022047911688_71" }{\fldrslt 
{\super \b0 \cf28 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, as required by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1944117044&pubNum=0000708&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Skidmore v. Swift & Co.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 323 U.S. 134, 65 S.Ct. 161, 89 L.Ed. 124 (1944)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1944117044&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Skidmore
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3frequires courts to give some deference to informal agency interpretations of ambiguous statutory dictates, with the degree of deference depending on the circumstances.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029677520&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1330&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1330" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Stephenson v. Office of Pers. Mgmt.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 705 F.3d 1323, 1330 (Fed. Cir. 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006329240&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cathedral Candle Co. v. U.S. Int\rquote l Trade Comm\rquote n
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 400 F.3d 1352, 1365 (Fed. Cir. 2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). These circumstances include \u8220\'3fthe agency\rquote s care, its consistency, formality, and relative expertness, [and] the persuasiveness of the agency\rquote s position.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001518724&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_228&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_228" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
United States v. Mead Corp.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 533 U.S. 218, 228, 121 S.Ct. 2164, 150 L.Ed.2d 292 (2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted). Cleveland Clinic further contends that the district court erred by not granting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1944117044&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Skidmore
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 deference to the examiner\rquote s decision to allow the patents\u8217\'3f applications to issue in light of the guidance, specifically Example 29\u8211\'3fClaim 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
True Health responds that the guidance is neither persuasive nor relevant to the eligibility of the claims at issue and the district court correctly found that the example claim is directed to a method of detecting a protein in a plasma sample without linking the results to a disease or other natural phenomenon.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Example 29 sets forth a hypothetical protein, \u8220\'3fJUL-1,\u8221\'3f which naturally occurs in people with an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic39e7bac475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
autoimmune disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fjulitis,\u8221\'3f but not in others. J.A. 1161\u8211\'3f63. The applicant discloses \u8220\'3froutine and conventional\u8221\'3f techniques, including an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib5ba9392475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoassay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib080612e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
spectroscopy
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, to detect the presence of the protein in a patient\rquote s plasma sample. J.A. 1161. The example claim is reproduced below:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Example 29\u8211\'3fClaim 1
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method of detecting JUL-1 in a patient, said method comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
a. obtaining a plasma sample from a human patient; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li600 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
b. detecting whether JUL-1 is present in the plasma sample by contacting the plasma sample with an anti-JUL-1 antibody and detecting binding between JUL-1 and the antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 1162.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In its guidance, the PTO advised that, because the claim does not \u8220\'3frecite or describe any [ineligible concept],\u8221\'3f it is not directed to a natural law and is eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. J.A. 1163.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We agree with True Health that the district court did not err in finding the instant claims ineligible. While we greatly respect the PTO\rquote s expertise on all matters relating to patentability, including patent eligibility, we are not bound by its guidance. And, especially regarding the issue of patent eligibility and the efforts of the courts to determine the distinction between claims directed to natural laws and those directed to patent-eligible applications of those laws, we are mindful of the need for consistent application of our case law.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Example 29\u8211\'3fClaim 1 is strikingly similar to claim 1 of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001585894&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=I0ae90e00746a11d7afb9df8873fee31a&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent 6,258,540
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at issue in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_6538_1021_71}{\*\bkmkend co_pp_sp_6538_1021_71}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1021
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 1. A method for detecting a paternally inherited nucleic acid of fetal origin performed on a maternal serum or plasma sample from a pregnant female, which method comprises
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
amplifying a paternally inherited nucleic acid from the serum or plasma sample and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
detecting the presence of a paternally inherited nucleic acid of fetal origin in the sample.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1373&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1373" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1373\u8211\'3f74
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we held this claim ineligible because it was directed to the discovery that paternally inherited cffDNA exists in maternal blood plasma, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1376
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the amplification and detection techniques were concededly known in the art. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1377\u8211\'3f78
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Likewise, Example 29 stipulates that the techniques used to detect JUL-1 were conventionally applied to detect any protein of interest. The only remaining non-conventional element of each claim is the discovery that the protein is present in the bodily sample, and the discovery of a natural law cannot by itself provide the requisite inventive concept. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000780&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_780_593&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_593" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Flook
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 437 U.S. at 593 n.15, 98 S.Ct. 2522
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that discovery of a natural phenomenon is not patentably novel because the phenomenon has always existed).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We have considered Example 29 and the arguments relating to it, but to the extent that Example 29\u8211\'3fClaim 1 is analogous to the claims at issue, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 must control. Accordingly, we decline to follow the PTO\rquote s Example 29\u8211\'3fClaim 1 and conclude that the district court did not err in its consideration of the PTO\rquote s subject matter eligibility guidance.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Finally, to the extent Cleveland Clinic argues that the district court should have deferred to the examiner\rquote s decision to allow the asserted claims, we have consistently held that any such deference is incorporated into the presumption of patent validity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS282&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf21 \f2 \i0 \fs20 \chcbpat29 
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf28 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 282
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030802772&pubNum=0000506&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=RP&fi=co_pp_sp_506_1357&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1357" }{\fldrslt 
{\b0 \cf28 \f2 \i1 \fs20 
{\b0 \cf28 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Novo Nordisk A/S v. Caraco Pharm. Labs., Ltd.
}
}
{\b0 \cf28 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 719 F.3d 1346, 1357 (Fed. Cir. 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which the district court recognized.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I3de57761090f11eb9c0dba44a5861}{\*\bkmkend co_anchor_I3de57761090f11eb9c0dba44a5861}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Conclusion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We have considered the rest of the parties\u8217\'3f arguments but find them unpersuasive. For the foregoing reasons, we 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
affirm
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the decision of the district court.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
AFFIRMED
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_71}{\*\bkmkend co_allCitations_71}
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
760 Fed.Appx. 1013
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012047911688_71}{\*\bkmkend co_footnote_B00012047911688_71}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012047911688_ID0EVEAE_71" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The patents each claim priority from an application which issued as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent 7,223,552
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and contain materially identical specifications. For consistency, our citations of their common specification refer to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041084069&pubNum=0004074&originatingDoc=I97f4851055ca11e98ad7980ccbaa346a&refType=PA&docFamilyGuid=Ieaeafb80fcb411e68128abc29f8e1e41&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f065 patent
}\b0 \cf28 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022047911688_71}{\*\bkmkend co_footnote_B00022047911688_71}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022047911688_ID0EHXAG_71" }{\fldrslt 
{\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf28 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Example 29, the disputed portion of the guidance, was published by the PTO on May 4, 2016. J.A. 1151.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf24 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf24 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf24 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf24 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf24 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf24 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf24 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf24 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }